VIP side effects and risks

Reported side effects

• Low blood pressure: IV TESICO: 58.4% versus 41.3% placebo during infusions. Nasal frequency is unknown., serious. Fainting or chest pain needs urgent care; IV trials used infusion pauses or slower rates. (source)
• Diarrhea: IV TESICO: 39.8% versus 11.3% placebo. US trial: 32.8% versus 1.5%., moderate. Persistent watery stools, poor fluid intake or dizziness need prompt assessment. (source)
• Flushing: IV TESICO: 14.7% versus 6.1% placebo during infusions., mild (source)
• Fast heart rate: IV TESICO: 9.5% versus 4.8% placebo during infusions., moderate. A sustained racing or irregular heartbeat, chest pain or faintness needs care. (source)
• Migraine or headache: Two hour IV challenge in migraine: 15/21, 71%, versus 1/21, 5%, with placebo. Nasal rate is unknown., moderate (source)
• Raised pancreatic enzyme: Nasal CIRS study: 1/20 had a transient lipase rise without belly pain. This is not a reliable population rate., moderate (source)
• Nasal fatigue, lightheadedness or no benefit: Mixed forum reports; no denominator or verified product identity., moderate (source)
• Priapism with the ED combination: VIP–phentolamine cohort: 1/308, 0.3%. This risk concerns penile injections., serious. An erection lasting 4 hours needs emergency care. (source)
• Severe immune or allergic reactions: FDA’s 2019 review noted severe immune reactions; no reliable rate or route specific denominator was supplied., serious. Swelling of the mouth or throat, wheezing or breathing trouble needs emergency care. (source)

Stop and get help if

• Fainting, chest pain or severe breathlessness: Stop exposure and seek emergency care.
• Face or tongue swelling, wheezing or trouble breathing: Seek emergency care for a possible severe allergic reaction.
• Severe persistent belly pain, repeated vomiting or inability to keep fluids down: Stop exposure and get urgent assessment.
• An erection lasting 4 hours after penile injection: Seek emergency care immediately; delayed care can damage penile tissue.
• A sudden severe headache, weakness, speech trouble or vision loss: Seek emergency care immediately.

Who should avoid it

• pregnant: Pregnancy safety is unproven; trials excluded pregnancy. One favorable case report cannot establish fetal safety.
• breastfeeding: Breast-milk transfer and infant effects are unknown; clinical trial eligibility excluded breastfeeding.
• tryingToConceive: Conception safety is unproven. A planned sarcoidosis trial excluded planned pregnancy and required contraception; no tested washout interval is established.
• under18: Adult trial evidence does not establish child safety. A small CIRS cohort including a minor is insufficient.
• other: Do not repeat dosing after a serious allergic reaction to VIP or its formulation.
• other: VIP can lower blood pressure. Existing symptomatic low pressure, fainting or dehydration raises immediate risk.
• heartCondition: Low blood pressure and faster heart rate can stress the heart; review cardiac status and medicines.
• uncontrolledBloodPressure: Large blood-pressure changes and interacting medicines need assessment before exposure.
• pancreatitisHistory: One nasal-study patient had raised lipase. Pancreatitis risk and safe use after pancreatitis are unknown.
• activeCancer: VIP supports blood-vessel and tumor signaling in lab models. This is a precaution; human cancer risk is unknown.
• cancerHistory: Discuss prior cancer with the treating team; human recurrence data for added VIP are lacking.
• other: Two-hour IV exposure provoked migraine; nasal and subcutaneous headache risk is not quantified.
• kidneyDisease: Dose adjustments are not established. Low pressure or diarrhea may worsen fluid and kidney problems.
• liverDisease: Formal dose-adjustment studies in liver impairment were not identified.
• diabetes: VIP can alter glucose and insulin signaling. Glucose response to community schedules is unpredictable.
• testedAthlete: No VIP-specific anti-doping decision was found; obtain a ruling for the exact substance and product.
• other: For intracavernosal VIP–phentolamine only: block with sickle-cell disease or trait, multiple myeloma, leukemia, or another condition predisposing to prolonged erections.
• other: For intracavernosal VIP–phentolamine only: block with penile angulation, cavernosal fibrosis or Peyronie's disease.
• other: For intracavernosal VIP–phentolamine only: a penile implant is a label contraindication.
• other: For intracavernosal VIP–phentolamine only: block when an underlying physical disease makes sexual activity inadvisable or contraindicated.
• other: TESICO IV exclusion: end-stage liver disease prevented enrollment. This trial restriction does not establish a contraindication for nasal or subcutaneous VIP.
• other: TESICO IV exclusion: severe diarrhea prevented enrollment. Infusion was withheld with more than 3 liquid stools in 24 hours; this restriction is not established for other routes.
• other: TESICO IV exclusion: current C. difficile infection prevented enrollment. This trial restriction does not establish a contraindication for nasal or subcutaneous VIP.

Interactions

• Blood-pressure medicines and vasodilators: Nasal VIP interactions are unstudied. Additive blood-pressure lowering is a theoretical concern; intracavernosal VIP–phentolamine has a separate label prohibition on other ED medicines.
• Insulin and sulfonylureas: VIP affects glucose and insulin biology. A clinical interaction size or routine adjustment is unknown; review glucose monitoring.
• Anticoagulants: The ED-combination label cautions about bleeding with penile injections. A systemic interaction with nasal VIP has not been established.
• Other VIP products or analogues: Duplicate VIP exposure can add vascular effects. Long-acting analogues have different kinetics; no dose conversion is established.
• Other ED medicines with intracavernosal VIP–phentolamine: For intracavernosal VIP–phentolamine only: do not combine with other ED medicines, including oral PDE5 inhibitors or penile injections, because erections may be prolonged.

Product quality risks

• No independent survey of online VIP products was found. General unauthorized-peptide warnings cannot establish a VIP-specific contamination rate.
• Unauthorized peptides may contain the wrong amount, the wrong ingredient, microbes, endotoxin or residual chemicals.
• A research-use label and a high purity percentage do not establish identity, dose accuracy or injection quality.
• The 2017 authors reported HPLC purity, stability, sterility and endotoxin testing of their nasal formulation; this does not certify other products.
• FDA’s 2019 review noted risks from wrong-length or wrong-sequence peptides when VIP synthesis is poorly controlled.